Techcyte adds Imagenomix EGFR prediction to Fusion AP

Techcyte is integrating Imagenomix’s Pulmogene-Predict into Fusion AP, starting with EGFR mutation prediction for research, translational and trial-enrichment use. The workflow uses routine H&E slide images to generate mutation scores and heatmaps without consuming additional tissue.

Why it matters: - The integration gives pathologists a way to explore molecular signals from routine H&E slides before sending tissue for sequencing. - The approach may help preserve small biopsy samples for confirmatory testing. - The workflow is aimed at research, translational work and clinical trial enrichment, where faster screening can improve cohort selection. - In lung cancer, the model addresses a gap where some patients never reach molecular testing because tissue is limited, sequencing is slow or both.

What happened: - Techcyte announced that it is integrating Pulmogene-Predict from Imagenomix into Fusion AP. - The first use case is EGFR mutation prediction in lung cancer. - The integration is designed for research, translational and clinical trial enrichment use. - Techcyte plans future expansion to additional biomarkers, including KRAS and TP53.

The details: - Pathologists can send routine hematoxylin and eosin, or H&E, whole-slide images from a Fusion AP case to Imagenomix’s cloud for analysis. - The results return to the Fusion case as a mutation score, a spatial heatmap and a PDF prediction report. - Pulmogene-Predict uses existing images, so it does not require additional stains or sections. - The system is meant to preserve limited biopsy material for confirmatory testing. - The workflow supports a screen-then-confirm research approach. - Archived H&E slides can also be screened to identify biomarker-positive cohorts for trial enrichment and discovery. - Techcyte CEO Ben Cahoon said the tool lets pathologists look at likely genotypes from the same slide they already have in front of them, while making the reflex NGS workflow more efficient. - Imagenomix CEO Travis Wold said the IGX Predict family was built to explore molecular information from existing H&E slides without consuming tissue. - Pulmogene-Predict is for Research Use Only and is not a clinical diagnostic. - Pulmogene-Predict does not replace next-generation sequencing or immunohistochemistry. - Techcyte Fusion AP is for Research Use Only in the United States and is not for diagnostic use.

Between the lines: - The partnership is as much about workflow as it is about AI prediction. - By placing molecular prediction inside a familiar slide-review environment, Techcyte and Imagenomix are trying to move biomarker screening earlier in the pathologist’s review process. - The screening-first model could help labs prioritize which cases need sequencing, especially when tissue is scarce. - The research-only positioning keeps the product away from clinical claims while still targeting translational and trial-enrichment use cases.

What's next: - Techcyte said the integration starts with EGFR and may expand to KRAS, TP53 and additional biomarkers. - Techcyte will showcase the integration at Pathology Visions, Booth 410, Oct. 16-18 in San Diego. - The companies plan to use the event to demonstrate how molecular prediction research can fit inside Fusion AP. - More information is available on Techcyte’s website and Imagenomix’s website.

The bottom line: - Techcyte and Imagenomix are combining digital pathology and AI to predict lung cancer biomarkers from standard H&E slides without using more tissue.